Evidence map›Paper›PMID 39839219›Full record

ArticleClinical practice and epidemiology in mental health : CP & EMH2024

Pharmacogenetic Testing in Treatment-resistant Panic Disorder: a Preliminary Analysis.

Marcos Fidry, Morena Mourao Zugliani, Mariana Costa do Cabo, Renan Machado Martins, Manuella Assad Gomez, Clara Gitahy Falcão Faria, Antonio Egidio Nardi, Rafael C Freire

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical practice and epidemiology in mental health : CP & EMH, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marcos FidryLaboratory of Panic and Respiration, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro (UFRJ). Rio de Janeiro, RJ, Brazil.
Morena Mourao ZuglianiLaboratory of Panic and Respiration, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro (UFRJ). Rio de Janeiro, RJ, Brazil.
Mariana Costa do CaboLaboratory of Panic and Respiration, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro (UFRJ). Rio de Janeiro, RJ, Brazil.
Renan Machado MartinsLaboratory of Panic and Respiration, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro (UFRJ). Rio de Janeiro, RJ, Brazil.
Manuella Assad GomezLaboratory of Panic and Respiration, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro (UFRJ). Rio de Janeiro, RJ, Brazil.
Clara Gitahy Falcão FariaLaboratory of Panic and Respiration, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro (UFRJ). Rio de Janeiro, RJ, Brazil.
Antonio Egidio NardiLaboratory of Panic and Respiration, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro (UFRJ). Rio de Janeiro, RJ, Brazil.
Rafael C FreireLaboratory of Panic and Respiration, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro (UFRJ). Rio de Janeiro, RJ, Brazil.ORCID https://orcid.org/0000-0003-3875-4601

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Many pharmacological treatments are considered effective in the treatment of panic disorder (PD), however, about 20 to 40% of the patients have treatment-resistant PD. Pharmacogenetics could explain why some patients are treatment-resistant. Objective: Our objective was to gather preliminary data on the clinical usefulness of pharmacogenetic testing in this disorder. Methods: Twenty patients with treatment-resistant PD were included in this observational study and submitted to commercial pharmacogenetic testing. Testing panel included gene polymorphisms related to CYP, genes Results: In 30% of the patients, the tests indicated reduced chance of response to the prescribed drug, while they indicated very low serum levels of the prescribed drug in 20% of the subjects. The pharmacogenetic tests predicted reduction of MTHFR enzyme activity in 74% of the patients. ABCB1 gene alleles associated to drug resistance were found in 90% of the samples. Conclusion: Commercial pharmacogenetic testing failed to predict negative treatment outcome in most patients with PD. The association between treatment-resistance in PD and the genes CYP2C19, MTHFR and ABCB1 deserves further study.

Indexed as

ABCB1 proteinCytochrome P450Folic acidMethylenetetrahydrofolate reductaseNeuropharmacologyPharmacokineticsTreatment-resistant anxiety disorder

Identifiers

PMID39839219
PMCPMC11748058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.